[Preparation of albendazole polybutycyanocrylate nanoparticles and study on its pharmaceutical properties and tissue distribution].
OBJECTIVE
To prepare the target drug delivery systems(TDDS), albendazole polybutycyanocrylate nanoparticles (ABZ-PBCA-NP), its pharmaceutical characters and tissue distributions were simultaneously investigated.


METHODS
Albendazole nanoparticles were prepared with the emulsification-polymerization method and the drug-load mechanism of polybutycyanocrylate nanoparticles was studied with the equal-tempaerature adsorption principle. The dialyse dynamic of albendazole from ABZ-PBCA-NP was investigated in four formulations in vitro. The tissue distribution of albendazole in different drug vehicles was studied with isotope labelling experiment.


RESULTS
ABZ-PBCA-NP and ABZ-PVP-PBCA-NP fit to the Higuchi and bi-exponent function in vitro respectively. The drug loaded in nanoparticles was abide by the Langmuir adsorption equation. Targeting index of albendazole in liver and spleen in mice are 11.4 and 3.9 after ig 3H-ABZ-PBCA-NP. The bioavailability of albendazole nanoparticle and suspension are 76.0% and 36.9% respectively.


CONCLUSIONS
The absorptive capability of drug was enhance when 4% PVP was added into the nanoparticle, and its release time was lengthen. At the same time, the nanoparticles vehicles increase the albendazole bioavailability.
D015766:Albendazole / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000493:pharmacokinetics; D001682:Biological Availability; D004337:Drug Carriers; D016503:Drug Delivery Systems; D004659:Enbucrilate / Q000737:chemistry; D005260:Female; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D036103:Nanotechnology; D010316:Particle Size; D013154:Spleen / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000379:methods; D014018:Tissue Distribution
D000871:Anthelmintics; D004337:Drug Carriers; D015766:Albendazole; D004659:Enbucrilate